Loading...
LAURUSLABS logo

Laurus Labs LimitedNSEI:LAURUSLABS Stock Report

Market Cap ₹532.9b
Share Price
₹978.20
My Fair Value
n/a
1Y90.8%
7D-2.1%
Portfolio Value
​
View

Laurus Labs Limited

NSEI:LAURUSLABS Stock Report

Market Cap: ₹532.9b

Laurus Labs (LAURUSLABS) Stock Overview

Manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. More details

LAURUSLABS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance4/6
Financial Health4/6
Dividends2/6

Rewards

Earnings are forecast to grow 24.93% per year

Earnings grew by 421.7% over the past year

Risk Analysis

Has a high level of debt


LAURUSLABS Community Fair Values

Create Narrative

See what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.

LAURUSLABS logo
Laurus Labs

LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings

Key Takeaways Enthusiasm centers on Laurus Labs' expansion in CDMO and diversified therapies, expecting swift returns from aggressive investment and new high-value segments. Risks include high debt, ongoing capital needs, regulatory obstacles, and global drug price pressures that could disrupt earnings and margin growth.
View narrative
₹815.86
FV
19.9% overvalued intrinsic discount
13.25%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
LAURUSLABS logo
Laurus Labs

Global Healthcare Regulation Will Squeeze Margins Amid Rising Costs

Key Takeaways Regulatory changes and sustainable manufacturing trends are set to elevate costs and compress margins, challenging Laurus Labs' long-term profitability. Shifts in industry focus and pricing pressures, combined with underperforming new divisions and intense competition, threaten growth and core business relevance.
View narrative
₹303.09
FV
222.7% overvalued intrinsic discount
11.96%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
LAURUSLABS logo
Laurus Labs

Digital Transformation And Affordable Generics Will Expand Global Markets

Key Takeaways Management's strategy leverages advanced technology and diversified platforms to drive structurally higher margins and accelerate both revenue and product pipeline growth. Investments in digitalization and new verticals position Laurus Labs for rapid market expansion, sustained earnings resilience, and efficient global opportunity capture.
View narrative
₹1.03k
FV
4.6% undervalued intrinsic discount
15.92%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
View Stock Community

Laurus Labs Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Laurus Labs
Historical stock prices
Current Share Price₹978.20
52 Week High₹1,033.50
52 Week Low₹486.85
Beta0.40
1 Month Change5.88%
3 Month Change11.27%
1 Year Change90.83%
3 Year Change114.89%
5 Year Change208.73%
Change since IPO918.11%

Recent News & Updates

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80

Oct 30
Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80

Recent updates

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80

Oct 30
Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80

With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For

Oct 19
With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For

Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly

Aug 31
Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly

Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%

Jul 20
Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%

Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Jun 11
Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

May 19
Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 27
Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Laurus Labs Limited (NSE:LAURUSLABS) Not Flying Under The Radar

Apr 07
Laurus Labs Limited (NSE:LAURUSLABS) Not Flying Under The Radar

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

Jan 27
Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next
User avatar

CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams

Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Extensively

Jan 25
These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Extensively

Laurus Labs Limited's (NSE:LAURUSLABS) P/S Is On The Mark

Jan 03
Laurus Labs Limited's (NSE:LAURUSLABS) P/S Is On The Mark

Shareholder Returns

LAURUSLABSIN PharmaceuticalsIN Market
7D-2.1%0.1%0.3%
1Y90.8%-0.03%6.9%

Return vs Industry: LAURUSLABS exceeded the Indian Pharmaceuticals industry which returned -0% over the past year.

Return vs Market: LAURUSLABS exceeded the Indian Market which returned 6.9% over the past year.

Price Volatility

Is LAURUSLABS's price volatile compared to industry and market?
LAURUSLABS volatility
LAURUSLABS Average Weekly Movement3.6%
Pharmaceuticals Industry Average Movement4.6%
Market Average Movement5.1%
10% most volatile stocks in IN Market8.5%
10% least volatile stocks in IN Market3.0%

Stable Share Price: LAURUSLABS has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: LAURUSLABS's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20056,167Satyanarayana Chavawww.lauruslabs.com

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products.

Laurus Labs Limited Fundamentals Summary

How do Laurus Labs's earnings and revenue compare to its market cap?
LAURUSLABS fundamental statistics
Market cap₹532.86b
Earnings (TTM)₹6.84b
Revenue (TTM)₹63.58b
77.2x
P/E Ratio
8.3x
P/S Ratio

Is LAURUSLABS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LAURUSLABS income statement (TTM)
Revenue₹63.58b
Cost of Revenue₹28.04b
Gross Profit₹35.54b
Other Expenses₹28.70b
Earnings₹6.84b

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)12.67
Gross Margin55.90%
Net Profit Margin10.76%
Debt/Equity Ratio43.6%

How did LAURUSLABS perform over the long term?

See historical performance and comparison

Dividends

0.2%
Current Dividend Yield
13%
Payout Ratio

Does LAURUSLABS pay a reliable dividends?

See LAURUSLABS dividend history and benchmarks
When do you need to buy LAURUSLABS by to receive an upcoming dividend?
Laurus Labs dividend dates
Ex Dividend DateOct 31 2025
Dividend Pay DateNov 22 2025
Days until Ex dividend22 days
Days until Dividend pay date0 days

Does LAURUSLABS pay a reliable dividends?

See LAURUSLABS dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/21 11:39
End of Day Share Price 2025/11/21 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Laurus Labs Limited is covered by 26 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
null nullAntique Stockbroking Ltd.
Vijayaraghavan SwaminathanAvendus Spark